Pu YS - Search Results

1

Malignant epithelioid angiomyolipoma of the kidney.

Huang KH, Huang CY, Chung SD, Pu YS, Shun CT, Chen J. Huang KH, et al. Among authors: pu ys. J Formos Med Assoc. 2007 Feb;106(2 Suppl):S51-4. doi: 10.1016/s0929-6646(09)60353-3. J Formos Med Assoc. 2007. PMID: 17493897 Free article.

2

Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.

Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Hour TC, et al. Among authors: pu ys. Prostate. 2002 May 15;51(3):211-8. doi: 10.1002/pros.10089. Prostate. 2002. PMID: 11967955

3

Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Anticancer Drugs. 2002 Mar;13(3):293-300. doi: 10.1097/00001813-200203000-00011. Anticancer Drugs. 2002. PMID: 11984073

4

Cytotoxicity of arsenic trioxide to transitional carcinoma cells.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Urology. 2002 Aug;60(2):346-50. doi: 10.1016/s0090-4295(02)01699-0. Urology. 2002. PMID: 12137851

5

Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS. Hour TC, et al. Among authors: pu ys. Anticancer Drugs. 2004 Sep;15(8):779-85. doi: 10.1097/00001813-200409000-00007. Anticancer Drugs. 2004. PMID: 15494640

6

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. Pu YS, et al. Biochem Pharmacol. 2006 Mar 14;71(6):751-60. doi: 10.1016/j.bcp.2005.12.009. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413505

7

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.

Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS. Lin CC, et al. Among authors: pu ys. Cancer. 2006 Mar 15;106(6):1269-75. doi: 10.1002/cncr.21738. Cancer. 2006. PMID: 16470604 Free article. Clinical Trial.

8

Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer.

Hour TC, Pu YS, Lin CC, Huang SW, Chen J, Chiu AW, Chen CJ, Huang CY. Hour TC, et al. Among authors: pu ys. Anticancer Res. 2006 Jan-Feb;26(1A):375-8. Anticancer Res. 2006. PMID: 16475721 Free article.

9

Primary amyloidosis of the urinary bladder.

Huang CY, Shun CT, Huang KH, Chen J, Pu YS. Huang CY, et al. Among authors: pu ys. J Formos Med Assoc. 2006 Feb;105(2):164-7. doi: 10.1016/S0929-6646(09)60339-9. J Formos Med Assoc. 2006. PMID: 16477338 Free article.

10

Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.

Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT. Huang SP, et al. Among authors: pu ys. Int J Cancer. 2006 Oct 15;119(8):1902-7. doi: 10.1002/ijc.22053. Int J Cancer. 2006. PMID: 16708371

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters